Myriad, Glivec, and the $1 Billion "Myth"
4/25/2013
More...
|
Speaking the Unspeakable
3/27/2013
More...
|
2012 in Review
12/19/2012
More...
|
Pharma Embraces Emerging Markets; They Don't Embrace Back
9/26/2012
More...
|
Patent Threats, and the Cheap Cost of R&D
8/30/2012
More...
|
6 Ways to Save Biotech
7/25/2012
More...
|
The Price of Togetherness
6/27/2012
More...
|
BioPharm Executive: Your American Society of Clinical Oncology Crib Sheet
5/30/2012
More...
|
BioPharm Executive: Shareholders Before Patients?
4/25/2012
More...
|
BioPharm Executive: Smaller is Smarter
3/28/2012
More...
|
BioPharm Executive: Bubble, Billions, or Both?
2/29/2012
More...
|
BioPharm Executive: Embracing Generics and Emerging Markets
1/25/2012
More...
|
BioPharm Executive: Top 10: 2011 in Review
12/14/2011
More...
|
BioPharm Executive: The Bad Old Days in Europe?
11/30/2011
More...
|
BioPharm Executive: FDA Gets the Message
10/26/2011
More...
|
BioPharm Executive: Too Big to Succeed?
9/29/2011
More...
|
BioPharm Executive: The Price of Confusion
9/1/2011
More...
|
BioPharm Executive: FDA, Faster Than Ever?
7/28/2011
More...
|
BioPharm Executive: Everything You Wanted to Know About ASCO (But Were Afraid to ASCO)
5/25/2011
More...
|
Biopharm Executive: Too Big to Be Responsible?
4/28/2011
More...
|
BioPharm Executive: Pure, Small Pharma
3/30/2011
More...
|
BioPharm Executive: We're All In This Together
2/23/2011
More...
|
BioPharm Executive: Going Mobile
1/27/2011
More...
|
BioPharm Executive: Top 10: 2010 In Review
12/15/2010
More...
|
BioPharm Executive: The Acceleration of Disgust
11/24/2010
More...
|
BioPharm Executive: Lilly's Shopping Plans Go Against the Grain
10/27/2010
More...
|
BioPharm Executive: Is Cancer's "Penicillin Moment" FDA's Moment of Doubt?
9/29/2010
More...
|
BioPharm Executive: Lilly, By Any Other Name...
8/25/2010
More...
|
BioPharm Executive: Firing Slows, but Lilly Fans the Flames
7/29/2010
More...
|
BioPharm Executive: Clean Up Your Act
6/30/2010
More...
|
BioPharm Executive: Hurry Up and Wait
4/28/2010
More...
|
BioPharm Executive: The New Decade Finally Begins
3/31/2010
More...
|
BioPharm Executive: This Is Recovery: Less Money, Less Risk Appetite, Fewer Jobs
2/24/2010
More...
|
BioPharm Executive: J.P. Morgan Healthcare Conference Sets the Tone for 2010
1/27/2010
More...
|
BioPharm Executive: Top 10: 2009 In Review
12/21/2009
More...
|
BioPharm Executive: Where'd the Jobs Go?
11/25/2009
More...
|
BioPharm Executive: No Sleep, But Plenty of REMS
10/28/2009
More...
|
BioPharm Executive: Vivus: Savior of the Pharma Industry?
9/30/2009
More...
|
BioPharm Executive: Biotech's Dog Days
8/26/2009
More...
|
BioPharm Executive: Sunshine, Lollipops, and Exclusivity
7/21/2009
More...
|
BioPharm Executive: Sprinting to the Finish
6/30/2009
More...
|
BioPharm Executive: Biotech's Green Shoots
5/27/2009
More...
|
BioPharm Executive: We Are All Activists Now
4/29/2009
More...
|
BioPharm Executive -- Biogenerics: The Time Has Come
3/31/2009
More...
|
BioPharm Executive: Big Pharma's Musical Chairs
2/25/2009
More...
|
BioPharm Executive: Off On the Right Hand in 2009
1/28/2009
More...
|
BioPharm Executive Top 10: 2008 in Review
12/18/2008
More...
|
BioPharm Executive: Change Comes to Biotech
11/25/2008
More...
|
BioPharm Executive: No Free Lunch
10/29/2008
More...
|
BioPharm Executive: There Goes Wall Street
9/30/2008
More...
|
BioPharm Executive: Biotech Money Goes to Democrats (Plus the Stupid Drug Name Olympics)
8/27/2008
More...
|
BioPharm Executive: Rethink Everything
7/30/2008
More...
|
Small is Beautiful -- BioPharm Executive
6/25/2008
More...
|
Taking the Gloves Off
5/26/2008
More...
|
Biotech Blossoms Anew
4/30/2008
More...
|
Time to Buy Biotech?
3/26/2008
More...
|
Biogenerics in '08?
2/26/2008
More...
|
Keeping Your Hands Clean
1/23/2008
More...
|
Desperate But Not Crazy
12/20/2007
More...
|
Dinosaurs and Drug Companies
11/20/2007
More...
|
Party Like It's 1999
10/23/2007
More...
|